BREAKTHROUGH: Pfizer’s COVID-19 Coronavirus Vaccine Estimated “90% Effective” Involving 40,000+ Patients
- November 9, 2020
- Posted by: Craig Chamberlin
- Category: Social Media
Looking forward to a bit of positivity is one great consequence of the days following the election. Although this election is certainly not settled, not by a long shot, it does appear we’ve been graced with excellent news this morning. Pfizer, a leading American pharmaceutical corporation, has announced the results of over 94 trials for their COVID-19 vaccine. It appears the vaccine may be a staggering 90% effective.
Here are the details:
- Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
- Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
- Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
- Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
- Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints
This is likely to bring comfort to many Americans who’ve been inundated by a media hell bent on terrifying them into oblivion over the COVID-19 pandemic. Although the concerns surrounding COVID-19 certainly are not unwarranted, this does appear to be another successful notch on Trump’s belt as a leader, he did promise we’d see a vaccine before the end of the year. Pfizer itself says it did not accept any funding from operation warp speed, but did accept the deal if federal resources were required to make the vaccine happen.
Although there are many steps to take prior to mass distribution, it is likely those who need the vaccine most will receive it first.